Legend Biotech Corp

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $49.1m
$57.3m +16.55%
$75.7m +32.15%
$68.8m -9.05%
$127.7m +85.55%
$285.1m +123.28%
$627.2m +119.97%
$1.0b +64.04%
$1.1b +10.70%
License and other revenue $35.3m $144.7m $84.1m
Collaboration revenue $0 $0 $66.7m $249.8m $482.6m $944.8m
Cost of collaboration revenue $0 $0 ($65.4m) ($144.2m) ($216.4m) ($397.1m)
Cost of license and other revenue $0 $0 ($18.2m) ($11.0m)
Cost of Goods and Services Sold $22.1m
$25.7m +16.55%
$34.0m +32.15%
$30.9m -9.05%
$65.4m +111.59%
$144.2m +120.64%
$216.4m +50.03%
$397.1m +83.53%
$512.7m +29.11%
Cost Of Revenue $65.4m
$144.2m +120.61%
$234.6m +62.69%
$408.1m +73.96%
$512.7m +25.63%
Net Interest Income ($2.6m)
$32.7m +1350.96%
$39.6m +21.10%
$18.7m -52.78%
$13.5m -27.81%
Gross Profit $27.1m
$31.6m +16.55%
$41.7m +32.15%
$37.9m -9.05%
$51.6m +36.13%
$140.9m +172.84%
$392.7m +178.71%
$620.8m +58.09%
$626.3m +0.89%
Gross Profit (Calculated) $27.1m
$31.6m +16.55%
$41.7m +32.15%
$37.9m -9.05%
$51.6m +36.13%
$140.9m +172.90%
$410.9m +191.55%
$631.8m +53.77%
Research and development $60.6m $161.9m $232.2m $313.3m $335.6m $382.2m $413.5m $414.7m $398.5m
Selling And Marketing Expense $93.4m $94.2m $147.5m $205.8m $359.2m
General And Administrative Expense $2.8m $6.8m $23.1m $47.0m $80.6m $106.8m $136.8m $135.8m $144.3m
Operating expenses:
Other Operating Expenses ($2.4m) $85.8m $4.4m $1.0m
Operating loss ($434.9m)
($528.1m) -21.42%
($309.5m) +41.39%
($136.5m) +55.90%
($134.6m) +1.39%
Other Non Operating Income Expenses ($9.0m) $3.4m $2.5m $4.0m
Interest Expense On Lease Liabilities $199k $195k $142k $527k $1.4m $1.8m $3.5m $21.8m
Interest Expense ($82k) $223k $4.2m $900k $10.8m $21.8m $21.6m $21.4m $21.8m
Interest Income $4.6m $2.9m $971k $8.2m $54.5m $61.2m $40.1m $35.3m
Net Non Operating Interest Income Expense ($2.6m) $32.7m $39.6m $18.7m $13.5m
Gain On Sale Of Security $21.5m ($28.2m) $109.3m ($168.8m) ($119.5m)
Other Income $7.1m $6.1m $2.7m $10.7m $57.5m $63.7m
Other Income Expense $12.5m ($24.8m) $111.8m ($164.8m) ($115.4m)
Pre-Tax Income ($1.6m) ($130.4m) ($307.6m) ($407.2m) ($445.7m) ($520.2m) ($158.1m) ($282.6m) ($236.5m)
Deferred Tax Expense (Income) Recognised In Profit Or Loss ($68.9m) ($8.0m)
Income Tax Expense Continuing Operations $1.2m $2.6m ($4.1m) ($3.6m) $625k ($1.9m) $18.9m $14.2m $13.6m
Net loss ($2.8m) ($133.0m) ($303.5m) ($386.2m) ($446.3m) ($518.3m) ($177.0m) ($296.8m)
Net Income From Continuing And Discontinued Operation ($2.8m) ($133.0m) ($303.5m) ($386.2m) ($446.3m) ($518.3m) ($177.0m) ($296.8m) ($250.1m)
Basic Earnings (Loss) Per Share ($0.01) ($0.66) ($1.28) ($1.43) ($1.40) ($1.47) ($0.48) ($0.81) ($1.38)
Diluted Earnings (Loss) Per Share ($0.01) ($0.66) ($1.28) ($1.43) ($1.40) ($1.47) ($0.48) ($0.81) ($1.38)
Basic Average Shares $159.0m $176.1m $182.9m $184.3m $184.7m
Diluted Average Shares $159.0m $176.1m $182.9m $184.3m $184.7m
Additional Financial Items
Average Effective Tax Rate ($0) $0 $0 ($0) $0 ($0) ($0)
Depreciation Right of Use Assets $1.2m $1.5m $4.4m $5.7m $7.8m $10.7m $19.5m
Finance Income $4.6m $2.9m $971k $8.2m $54.5m $61.2m $40.1m
Impairment Loss Recognised In Profit Or Loss Property Plant And Equipment Including Right of Use Assets $4.4m $1.0m
Profit Loss Attributable To Owners Of Parent ($133.0m) ($303.5m) ($403.6m) ($446.3m) ($518.3m) ($177.0m)
Profit Loss Before Tax ($1.6m) ($130.4m) ($307.6m) ($407.2m) ($445.7m) ($520.1m) ($158.1m) ($282.6m)
Profit Loss From Operating Activities ($136.5m)
Tax Rate Effect Of Foreign Tax Rates ($0) ($0) ($0) ($0) ($0)
Exchange differences on translation of foreign operations ($1.4m) $182k ($2.1m) $10.6m $9.8m $29.6m ($112.5m) $190.4m
Other comprehensive income/(loss), net of tax ($1.4m) $182k ($2.1m) $10.6m $9.8m $29.6m ($112.5m) $190.4m
Diluted EPS ($2.80) ($2.94) ($0.96) ($1.62) ($1.38)
Diluted NI Availto Com Stockholders ($2.8m) ($133.0m) ($303.5m) ($386.2m) ($446.3m) ($518.3m) ($177.0m) ($296.8m) ($250.1m)
Impairment Of Capital Assets $0 $0 $4.4m $5.4m
Normalized EBITDA ($438.0m) ($451.7m) ($224.4m) ($63.5m) ($175.3m)
Normalized Income ($463.3m) ($490.2m) ($263.3m) ($163.4m) ($178.4m)
Other Gand A $2.8m $6.8m $23.1m $47.0m $80.6m $106.8m $136.8m $135.8m
Reconciled Depreciation $18.4m $18.5m $21.4m $28.9m $39.4m
Selling General And Administration $174.0m $201.0m $284.3m $341.6m
Special Income Charges $0 $0 ($4.4m) ($5.4m)
Tax Effect Of Unusual Items $4.5m ($103k) $23.0m ($35.4m) ($47.8m)
Tax Provision $625k ($1.9m) $18.9m $14.2m $13.6m
Tax Rate For Calcs $0 $0 $0 $0 $0
Write Off $0 $0 $4.4m $4.4m
Administrative Expense $2.8m $6.8m $23.1m $47.0m $80.6m $106.8m $136.8m $135.8m
Employee Benefits Expense $391.6m $492.3m
Expense From Share-Based Payment Transactions With Employees $1.3m $4.8m $20.2m $34.3m $47.7m $68.9m $64.6m
Expense Relating To Short-Term Leases For Which Recognition Exemption Has Been Used $272k $69k $182k $1.1m $2.3m $3.5m $3.7m
Finance Costs ($82k) $223k $4.2m $900k $10.8m $21.8m $21.6m $21.4m
Other Employee Expense $9.9m $10.6m
Selling and distribution expenses ($1.2m) ($25.6m) ($49.6m) ($102.5m) ($93.4m) ($94.2m) ($147.5m) ($205.8m)
Other (expense)/ income, net ($24.8m) $111.8m ($164.8m)
Operating Expense $507.3m $669.0m $702.2m $757.3m $760.9m
TOTAL COMPREHENSIVE LOSS ($4.2m) ($132.8m) ($305.6m) ($375.6m) ($436.5m) ($488.6m) ($289.5m) ($106.4m)
Total Unusual Items $21.5m ($28.2m) $109.3m ($168.8m) ($119.5m)
Total Expenses $572.6m $813.2m $936.8m $1.2b $1.3b

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.